180 related articles for article (PubMed ID: 31129769)
1. Combined loss of TFF3 and PTEN is associated with lethal outcome and overall survival in men with prostate cancer.
Abou-Ouf H; Ghosh S; Box A; Palanisamy N; Bismar TA
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1751-1759. PubMed ID: 31129769
[TBL] [Abstract][Full Text] [Related]
2. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
[TBL] [Abstract][Full Text] [Related]
3. Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.
Hamid AA; Gray KP; Huang Y; Bowden M; Pomerantz M; Loda M; Sweeney CJ
Eur Urol Oncol; 2019 Sep; 2(5):475-482. PubMed ID: 31411988
[TBL] [Abstract][Full Text] [Related]
4. High Serine-arginine Protein Kinase 1 Expression with PTEN Loss Defines Aggressive Phenotype of Prostate Cancer Associated with Lethal Outcome and Decreased Overall Survival.
Abou-Ouf H; Assem H; Ghosh S; Karnes RJ; Stoletov K; Palanisamy N; Lewis JD; Bismar TA
Eur Urol Open Sci; 2021 Jan; 23():1-8. PubMed ID: 34337483
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification.
Bismar TA; Hegazy S; Feng Z; Yu D; Donnelly B; Palanisamy N; Trock BJ
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2117-2125. PubMed ID: 30101374
[TBL] [Abstract][Full Text] [Related]
6. PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance.
Lokman U; Erickson AM; Vasarainen H; Rannikko AS; Mirtti T
Eur Urol Focus; 2018 Dec; 4(6):867-873. PubMed ID: 28753869
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.
Terry S; Nicolaiew N; Basset V; Semprez F; Soyeux P; Maillé P; Vacherot F; Ploussard G; Londoño-Vallejo A; de la Taille A; Allory Y
Cancer; 2015 May; 121(9):1422-30. PubMed ID: 25639219
[TBL] [Abstract][Full Text] [Related]
8. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.
Ahearn TU; Pettersson A; Ebot EM; Gerke T; Graff RE; Morais CL; Hicks JL; Wilson KM; Rider JR; Sesso HD; Fiorentino M; Flavin R; Finn S; Giovannucci EL; Loda M; Stampfer MJ; De Marzo AM; Mucci LA; Lotan TL
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26615022
[TBL] [Abstract][Full Text] [Related]
9. The 17-Gene Genomic Prostate Score Assay Predicts Outcome After Radical Prostatectomy Independent of PTEN Status.
Magi-Galluzzi C; Isharwal S; Falzarano SM; Tsiatis A; Dee A; Maddala T; Knezevic D; Febbo PG; Lawrence J; Klein EA
Urology; 2018 Nov; 121():132-138. PubMed ID: 30142405
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy.
Huang KC; Alshalalfa M; Hegazy SA; Dolph M; Donnelly B; Bismar TA
Cancer Biol Ther; 2014 Sep; 15(9):1120-8. PubMed ID: 24972028
[TBL] [Abstract][Full Text] [Related]
11. PTEN, ERG, SPINK1, and TFF3 Status and Relationship in a Prostate Cancer Cohort from Jordanian Arab Population.
Al Bashir S; Alorjani MS; Kheirallah K; Al Hamad M; Haddad HK; Al-Dwairy A; Bani-Fawwaz BA; Aldaoud N; Halalsheh O; Amawi S; Matalka II
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256434
[No Abstract] [Full Text] [Related]
12. Decreased ATM Protein Expression Is Substantiated with PTEN Loss in Defining Aggressive Phenotype of Prostate Cancer Associated with Lethal Disease.
Walker SR; Abdelsalam R; Ghosh S; Livingstone J; Palanisamy N; Boutros PC; Yip SM; Lees-Miller SP; Bismar TA
Eur Urol Open Sci; 2021 Jul; 29():93-101. PubMed ID: 34337539
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer.
Kim SH; Kim SH; Joung JY; Lee GK; Hong EK; Kang KM; Yu A; Nam BH; Chung J; Seo HK; Park WS; Lee KH
PLoS One; 2015; 10(4):e0122498. PubMed ID: 25897494
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.
Cuzick J; Yang ZH; Fisher G; Tikishvili E; Stone S; Lanchbury JS; Camacho N; Merson S; Brewer D; Cooper CS; Clark J; Berney DM; Møller H; Scardino P; Sangale Z;
Br J Cancer; 2013 Jun; 108(12):2582-9. PubMed ID: 23695019
[TBL] [Abstract][Full Text] [Related]
15. SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.
Huang KC; Evans A; Donnelly B; Bismar TA
Pathol Oncol Res; 2017 Apr; 23(2):399-407. PubMed ID: 27738792
[TBL] [Abstract][Full Text] [Related]
16. Association of mTOR Pathway Markers and Clinical Outcomes in Patients with Intermediate-/High-risk Prostate Cancer: Long-Term Analysis.
Barata PC; Magi-Galluzzi C; Gupta R; Dreicer R; Klein EA; Garcia JA
Clin Genitourin Cancer; 2019 Oct; 17(5):366-372. PubMed ID: 31262501
[TBL] [Abstract][Full Text] [Related]
17. Loss of KLK4::KLKP1 pseudogene expression by RNA chromogenic in-situ hybridization is associated with PTEN loss and increased risk of biochemical recurrence in a cohort of middle eastern men with prostate cancer.
Bakker A; Slack JC; Palanisamy N; Carskadon S; Ghosh S; Khalifeh I; Bismar TA
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3721-3728. PubMed ID: 35982181
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.
Nørgaard M; Haldrup C; Storebjerg TM; Vestergaard EM; Wild PJ; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28930171
[TBL] [Abstract][Full Text] [Related]
19. Investigating the role of the IGF axis as a predictor of biochemical recurrence in prostate cancer patients post-surgery.
Breen KJ; O'Neill A; Murphy L; Fan Y; Boyce S; Fitzgerald N; Dorris E; Brady L; Finn SP; Hayes BD; Treacy A; Barrett C; Aziz MA; Kay EW; Fitzpatrick JM; Watson RWG
Prostate; 2017 Sep; 77(12):1288-1300. PubMed ID: 28726241
[TBL] [Abstract][Full Text] [Related]
20. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
